Socioeconomic gradients in tiotropium use among adults with COPD

International Journal of COPD

Volumn 3, Issue 3, 2008, Pages 483-490

  Blanc, Paul D ^a   Eisner, Mark D ^a   Yelin, Edward H ^a   Earnest, Gillian ^a   Balmes, John R ^a   Gregorich, Steven E ^b   Katz, Patricia P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

COPD; Health gradients; Medication; Socioeconomic status; Tiotropium

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; OXYGEN; TIOTROPIUM BROMIDE;

ACADEMIC ACHIEVEMENT; ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; RISK ASSESSMENT; SOCIOECONOMICS; STRUCTURED INTERVIEW;

ADULT; AGED; CHOLINERGIC ANTAGONISTS; COHORT STUDIES; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; SOCIAL CLASS; SPIROMETRY; UNITED STATES;

EID: 54949137652     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Adler NE, Rehkopf DH. 2008. U.S. disparities in health: descriptions, causes, and mechanisms. Ann Rev Public Health, 29:235-52.
2. Anon. 2004. Tiotropium (Spiriva) for COPD. Med Lett Drugs Ther, 46:41-2.
3. Anon. 2007. Aformoterol (Brovana) for COPD. Med Lett Drugs Ther, 49:53-4.
4. Blanc PD, Eisner MD, Trupin L, et al. 2004. The association between occupational factors and adverse health outcomes in chronic obstructive pulmonary disease. Occup Environ Med, 61:661-7.
5. Buist AS, McBurnie MA, Vollmer WM, et al. 2007. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet, 370:741-50.
6. Chen H, Eisner MD, Katz PP, et al. 2006. Measuring disease-specific quality of life in obstructive airway disease: validation of a modified version of the airways questionnaire 20 (AQ20). Chest, 129:1644-52.
7. D'Souza AO, Smith MJ, Miller LA, et al. 2006. An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. Chest, 129:1693-708.
8. Eisner MD, Trupin L, Katz PP, et al. 2005. Development and validation of a survey-based COPD severity score. Chest, 127:1890-7.
9. Eisner MD, Katz P, Iribarren C, et al. 2007. Measurement of COPD severity: further validation of a survey-based instrument [Abstract]. Eur Resp J, 30:629S.
10. [GOLD] Global Initiative for Chronic Obstructive Lung Disease. 2006. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [online]. Accessed on January 14, 2008. URL: http://goldcopd.org.
11. Hankinson JL, Odencrantz JR, Fedan KB. 1999. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med, 159:179-87.
12. Kozyrskyj AL, Mustard CA, Simons FE. 2001. Socioeconomic status, drug insurance benefits, and new prescriptions for inhaled corticosteroids in schoolchildren with asthma. Arch Pediatr Adolesc Med, 155:1219-24.
13. Mannino DM, Buist AS. 2007. Global burden of COPD: risk factors, prevalence, and future trends. Lancet, 370:765-73.
14. Menezes AMB, Perez-Padillo R, Jardim JRB, et al. 2005. Chronic obstructive pulmonary disease m five Latin American cities (the PLATINO study): a prevalence study. Lancet, 366:1875-81.
15. Miller MR, Hankinson J, Brusasco V, et al. 2005. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J, 26:319-38
16. Rutten-van Mölken MPMH, Oostenbrink JB, Miravitlles M, et al. 2007. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipatropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ, 8:123-35.
17. Spence ME, Hui R, Chan J. 2006. Cost reduction strategies by elderly patents with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit. J Manag Care Pharm, 12:377-82.
18. Trupin L, Earnest G, San Pedro M, et al. 2003. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J, 22:462-9.
19. Warren JR, Hernandez EM. 2007. Did socioeconomic inequalities in morbidity and mortality change in the United States over the course of the twentieth century? J Health Soc Behav, 48:335-51.